A Medical Device and Digital Health company leveraging machine learning, predictive analytics and the first IoT medical device ever cleared by the FDA for the NICU. NFANT Labs’ mission is to improve outcomes and expedite safe transition of infants to full oral feeding.
Up to 70% of infants born prematurely and 10% of infants born full term have trouble transitioning to breast or bottle feeding on their own. Troubles with feeding can result in significant health problems for the infant such as apnea (infant stops breathing) and bradycardia (infant’s heart rate becomes abnormally slow) even extending to the parents who regularly exhibit PTSD symptoms. Yet, preterm oral feeding in general has been understudied and underserved resulting in limited evidence-based practice guidelines and clinical teams that work work in silos.
These reasons compelled NFANT Labs co-founders Dr. Gilson Capilouto, a clinician with over 30 years of experience in pediatric feeding, and Dr. Tommy Cunningham, an engineer with an expertise in biomechanics, to develop nfant® Feeding Solution, the first noninvasive diagnostic tool to measure tongue dynamics during feeding.
The nfant Feeding Solution transforms a generic bottle into a smart bottle providing clinicians with objective, actionable data, displayed in real time, on feeding readiness and the impact of each intervention. The data is then sent to nfant Analytics, a HIPAA and HITECH compliant web portal allowing clinicians to view and manage patients by displaying key feeding metrics relative to full terms. Leveraging advances in machine learning and predictive analytics, measures are analyzed and results relayed to the healthcare team to coordinate daily feeding treatments, determine the most at risk infants for resource allocation and track progress through discharge.
Additionally, NFANT Labs recognized an opportunity to support the intervention aspect of feeding and developed nfant Nipples. Bottle nipples with varying flow rates can have a drastic effect on an infant’s ability to feed safely and nfant Nipples’ highly controlled flow rates ensure a consistent feeding to feeding experience.
NFANT Labs will continue to push the edge of innovation for this fragile population and the professionals and families that care for them.
Lou Malice has worked in the field of medical device commercialization, research and development, manufacturing, supply chain management, quality and regulatory for more than 30 years. He is an active consultant in the Atlanta medical device community. He was an original employee and COO of Endochoice, Inc., a manufacturer and distributor of products serving gastro-intestinal professionals. EndoChoice executed an IPO and has since been acquired by Boston Scientific. Prior, Lou was Co-Founder of American Breast Care, manufacturer and distributor of products for women after breast surgery, that he exited in 2007.
Now, he is CEO of Nfant Labs, a provider of technology to the NICU for measuring a baby’s ability to properly feed. He also, sits on three Boards of medical device and digital health companies, as well as advising other startups.
Lou is a native of Atlanta and obtained his B.S in Industrial Management from Georgia Tech. He also holds six US Patents.